
OPKO Health (OPK) Stock Forecast & Price Target
OPKO Health (OPK) Analyst Ratings
Bulls say
OPKO Health is facing challenges in their diagnostics segment as reflected by its $13.0 million operating loss and lack of cost reductions. Although they had hoped to break even in Q4/25, this does not seem likely based on management's commentary and this quarter's annualized adjusted EBITDA loss of $36.4 million. Even the promising 4KScore test showed a decline in revenue from the previous year. This, combined with other factors such as the lack of cost and expense reductions, leads to a diminished outlook for the company in the near future.
Bears say
OPKO Health is facing challenges in meeting their financial guidance for FY/26 and may be unable to achieve the upper end of their revenue projections, causing concern. Additionally, their diagnostics business showed an operating loss in the quarter, despite expectations of at least breaking even. The company has potential for cost reduction but it is unclear if it will be enough to support profitable growth in 2026.
This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.
OPKO Health (OPK) Analyst Forecast & Price Prediction
Start investing in OPKO Health (OPK)
Order type
Buy in
Order amount
Est. shares
0 shares